{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:39:10Z","timestamp":1792395550788,"version":"4.4.0"},"reference-count":22,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>We report long\u2010term outcomes from a prospective Phase II trial of two cycles of preoperative S\u20101 plus oxaliplatin (SOX) chemotherapy in patients with clinical Stage III gastric cancer (GC), with at least 7 years of follow\u2010up for all surviving patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients received two cycles of preoperative SOX followed by laparoscopic D2 gastrectomy and postoperative adjuvant therapy. Overall survival (OS), relapse\u2010free survival (RFS), treatment compliance, and clinically documented late adverse events were evaluated. Associations between clinicopathological factors and survival were explored using Kaplan\u2013Meier analysis and the log\u2010rank test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty\u2010four patients were analyzed. Preoperative SOX completion was 100%, with clinical and pathological response rates of 73.5% and 58.8%, respectively. R0 resection was achieved in 97.1%, and adjuvant therapy was initiated in 94.1% and completed in 61.8%. At analysis, 18 patients had died and 16 remained alive; all survivors had at least 7 years of follow\u2010up and none were lost to follow\u2010up. Five\u2010year OS and RFS were 61.8% and 58.8%, respectively. In exploratory analyses, ypN0\u20131 status and a preoperative neutrophil\u2010to\u2010lymphocyte ratio &lt;\u00a04.3 were associated with better OS and RFS. No severe treatment\u2010related late adverse events were documented during routine follow\u2010up, although late toxicities were not systematically assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Two\u2010cycle preoperative SOX was highly feasible, with high treatment compliance and favorable long\u2010term outcomes in this prospective single\u2010arm cohort. Associations of ypN status and preoperative neutrophil\u2010to\u2010lymphocyte ratio with long\u2010term outcomes were exploratory and require validation in larger comparative studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>UMIN000036139.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajco.70214","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:39:17Z","timestamp":1792391957000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Minimum 7\u2010Year Follow\u2010Up of a Prospective Phase II Trial of Preoperative S\u20101 Plus Oxaliplatin Chemotherapy for Clinical Stage III Gastric Cancer"],"prefix":"10.1111","author":[{"given":"Sayuri","family":"Konishi","sequence":"first","affiliation":[{"name":"Department of Surgery Gastrointestinal Center Kyoto Katsura Hospital  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Manaka","sequence":"additional","affiliation":[{"name":"Department of Surgery Gastrointestinal Center Kyoto Katsura Hospital  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Surgery Gastrointestinal Center Kyoto Katsura Hospital  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Surgery Gastrointestinal Center Kyoto Katsura Hospital  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Surgery Gastrointestinal Center Kyoto Katsura Hospital  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Surgery Gastrointestinal Center Kyoto Katsura Hospital  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michina","family":"Morioka","sequence":"additional","affiliation":[{"name":"Department of Surgery Gastrointestinal Center Kyoto Katsura Hospital  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Surgery Gastrointestinal Center Kyoto Katsura Hospital  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Oncology Kyoto Katsura Hospital  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehiko","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Gastrointestinal Center Kyoto Katsura Hospital  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,18]]},"reference":[{"issue":"18","key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa072252","article-title":"Adjuvant Chemotherapy for Gastric Cancer With S\u20101, an Oral Fluoropyrimidine","volume":"357","author":"Sakuramoto S.","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(18)30383\u20102"},{"issue":"9813","key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","article-title":"Adjuvant Capecitabine and Oxaliplatin for Gastric Cancer After D2 Gastrectomy (CLASSIC): A Phase 3 Open\u2010Label, Randomised Controlled Trial","volume":"379","author":"Bang Y. J.","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative Chemotherapy Versus Surgery Alone for Resectable Gastroesophageal Cancer","volume":"355","author":"Cunningham D.","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(18)32557\u20101"},{"issue":"25","key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.23.02167","article-title":"Neoadjuvant Docetaxel, Oxaliplatin, and S\u20101 Plus Surgery and Adjuvant S\u20101 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY","volume":"42","author":"Kang Y. K.","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ags3.12352","article-title":"Primary Results of a Randomized Two\u2010By\u2010two Factorial Phase II Trial Comparing Neoadjuvant Chemotherapy With Two and Four Courses of Cisplatin\/S\u20101 and Docetaxel\/Cisplatin\/S\u20101 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer","volume":"4","author":"Hayashi T.","year":"2020","journal-title":"Annals of Gastroenterological Surgery"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(21)00297\u20107"},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s10120-020-01136-7","article-title":"Gastrectomy With or Without Neoadjuvant S\u20101 Plus Cisplatin for Type 4 or Large Type 3 Gastric Cancer (JCOG0501): An Open\u2010Label, Phase 3, Randomized Controlled Trial","volume":"24","author":"Iwasaki Y.","year":"2021","journal-title":"Gastric Cancer"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.31038\/CST.2021634"},{"issue":"1","key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-016-0622-4","article-title":"Japanese Gastric Cancer Treatment Guidelines 2014 (ver. 4)","volume":"20","author":"Japanese Gastric Cancer Association","year":"2017","journal-title":"Gastric Cancer"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10120\u2010011\u20100041\u20105"},{"issue":"1","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for Rating Diagnostic Tests","volume":"3","author":"Youden W. J.","year":"1950","journal-title":"Cancer"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434\u2010018\u20106471\u20100"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.7692"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13089"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7862469"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10120\u2010019\u201001027\u20106"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(24)00156\u20100"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(23)00541\u20107"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1782029"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.70214","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.70214","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.70214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:39:18Z","timestamp":1792391958000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.70214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,18]]},"references-count":22,"alternative-id":["10.1111\/ajco.70214"],"URL":"https:\/\/doi.org\/10.1111\/ajco.70214","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,18]]},"assertion":[{"value":"2026-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ajco.70214"}}